Biotechnology investors are familiar with Clovis Oncology (NASDAQ:CLVS). The company’s stock is beaten down (down over 90% from the 2017 high) after the company lost the PARP inhibitor race to competition like AstraZeneca (AZN) and sales of its PARP inhibitor Rubraca did not meet analyst expectations.
Similarly, Will Clovis Oncology go up?
The 4 analysts offering 12-month price forecasts for Clovis Oncology Inc have a median target of 4.00, with a high estimate of 8.00 and a low estimate of 1.50. The median estimate represents a +54.74% increase from the last price of 2.59.
What does Clovis Oncology do? Founded in 2009, Clovis Oncology (NASDAQ: CLVS) is a commercial stage biotechnology company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets.
Thereof, Why did Clovis Oncology stock go Up?
Why Clovis Oncology Stock Skyrocketed 80% This Week
Shares of Clovis Oncology (NASDAQ: CLVS) jumped 80% this week, according to data from S&P Global Market Intelligence. Clovis’ big move didn’t come until Thursday, however, when the company announced positive data regarding its drug Rubraca (rucaparib).
Who founded Clovis Oncology?
Clovis Oncology is an American pharmaceutical company which mainly markets products for treatment in oncology. Clovis was founded in 2009 and is headquartered in Boulder, Colorado.
…
Clovis Oncology.
| Type | Public |
|---|---|
| Founder | Patrick Mahaffy |
| Headquarters | Boulder, Colorado , U.S. |
| Revenue | $165 Million(2020) |
| Number of employees | 429 |
Who is the CEO of Clovis Oncology?
President/CEO/Co-Founder, Clovis Oncology Inc.
When did Clovis Oncology go public?
In addition, the underwriters have a 30-day option to purchase up to an additional 1,500,000 shares of common stock from Clovis Oncology to cover over-allotments, if any. Shares of Clovis Oncology’s common stock will trade on the NASDAQ Global Select Market under the symbol « CLVS » beginning on November 16, 2011.
Is Clovis Oncology a good stock?
The Clovis Oncology stock holds a sell signal from the short-term moving average; at the same time, however, there is a buy signal from the long-term average. Since the short-term average is above the long-term average there is a general buy signal in the stock giving a positive forecast for the stock.
What is the short interest on Clvs?
Clovis Oncology currently has a short interest ratio of 6.0. Learn More on Clovis Oncology’s short interest ratio.
Who owns Clvs?
Top 10 Owners of Clovis Oncology Inc
| Stockholder | Stake | Shares owned |
|---|---|---|
| The Vanguard Group, Inc. | 6.90% | 9,820,571 |
| BlackRock Fund Advisors | 5.82% | 8,284,149 |
| Palo Alto Investors LP | 2.81% | 3,997,826 |
| Geode Capital Management LLC | 1.56% | 2,212,612 |
Does CLV pay dividends?
CLOVIS ONCOLOGY (NASDAQ: CLVS) does not pay a dividend.
Is Clvs shorted?
Short Shares Availability
This table shows the number of shares of US:CLVS available to be shorted at a leading prime brokerage. It is not the total number of shares available to short, nor is it the short interest.
How much is Clvs shorted?
Short Interest: CLVS (NASDAQ)
| Clovis Oncology Incorporated | $ 2.65 |
|---|---|
| CLVS (NASDAQ) | -0.14 |
Join TheMoney.co community and don’t forget to share this post !
